7月14日,复宏汉霖宣布,公司创新型抗HER2单抗HLX22对比一线标准疗法的国际多中心3期研究(HLX22-GC-301)完成美国首例患者给药,拟用于联合曲妥珠单抗及化疗一线治疗HER2阳性晚期胃癌。HLX22-GC-301由北京大学肿瘤医院沈琳教授与NCCN胃癌与食管癌专委会主席,MD安德森癌症中心的Jaffer A. Ajan教授牵头开展,此前已于中国、日本、澳大利亚、韩国完成首例受试者给药...
Source Link7月14日,复宏汉霖宣布,公司创新型抗HER2单抗HLX22对比一线标准疗法的国际多中心3期研究(HLX22-GC-301)完成美国首例患者给药,拟用于联合曲妥珠单抗及化疗一线治疗HER2阳性晚期胃癌。HLX22-GC-301由北京大学肿瘤医院沈琳教授与NCCN胃癌与食管癌专委会主席,MD安德森癌症中心的Jaffer A. Ajan教授牵头开展,此前已于中国、日本、澳大利亚、韩国完成首例受试者给药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.